KR102180660B1 - 발현 방법 - Google Patents

발현 방법 Download PDF

Info

Publication number
KR102180660B1
KR102180660B1 KR1020157032562A KR20157032562A KR102180660B1 KR 102180660 B1 KR102180660 B1 KR 102180660B1 KR 1020157032562 A KR1020157032562 A KR 1020157032562A KR 20157032562 A KR20157032562 A KR 20157032562A KR 102180660 B1 KR102180660 B1 KR 102180660B1
Authority
KR
South Korea
Prior art keywords
sequence
cho
expression
cells
target polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157032562A
Other languages
English (en)
Korean (ko)
Other versions
KR20160003705A (ko
Inventor
페이 루이스 손더스
안나 루이스 도즈
아델린 마리 제럴딘 배야드
버펜드라 밸러브 카라
Original Assignee
후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed by 후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드 filed Critical 후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드
Publication of KR20160003705A publication Critical patent/KR20160003705A/ko
Application granted granted Critical
Publication of KR102180660B1 publication Critical patent/KR102180660B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
KR1020157032562A 2013-05-03 2014-04-29 발현 방법 Active KR102180660B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB1308017.1 2013-05-03
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
GB1320339.3 2013-11-18
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (2)

Publication Number Publication Date
KR20160003705A KR20160003705A (ko) 2016-01-11
KR102180660B1 true KR102180660B1 (ko) 2020-11-19

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157032562A Active KR102180660B1 (ko) 2013-05-03 2014-04-29 발현 방법

Country Status (12)

Country Link
US (3) US9873891B2 (enExample)
EP (1) EP2992104B1 (enExample)
JP (1) JP6545153B2 (enExample)
KR (1) KR102180660B1 (enExample)
CN (2) CN114395584B (enExample)
BR (1) BR112015027373A2 (enExample)
CA (1) CA2910877C (enExample)
DK (1) DK2992104T3 (enExample)
ES (1) ES2732907T3 (enExample)
RU (1) RU2731717C2 (enExample)
SG (1) SG11201508447TA (enExample)
WO (1) WO2014177826A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
JP7032438B2 (ja) 2017-12-11 2022-03-08 富士フイルム株式会社 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
EP3896168A4 (en) 2018-12-11 2022-03-02 FUJIFILM Corporation ANIMAL CELLS, METHODS OF PRODUCTION OF ANIMAL CELLS AND METHODS OF PRODUCTION OF TARGET PROTEIN
CN109837277A (zh) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 一种cpgk嵌合型启动子、腺相关病毒载体及其应用
WO2021107123A1 (ja) 2019-11-29 2021-06-03 富士フイルム株式会社 細胞培養方法、抗体製造方法、有機酸除去方法、及び、抗体
EP4276167A1 (en) 2021-01-07 2023-11-15 FUJIFILM Corporation Cell selection method, device and device system
WO2022196710A1 (ja) 2021-03-17 2022-09-22 富士フイルム株式会社 細胞培養方法、及び有用物質の製造方法
CN112980852B (zh) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
JP2024521784A (ja) 2021-05-27 2024-06-04 ヤンセン バイオテツク，インコーポレーテツド 前立腺がんの治療のための組成物及び方法
JPWO2023054556A1 (enExample) 2021-09-30 2023-04-06
JPWO2023112952A1 (enExample) 2021-12-15 2023-06-22
WO2023190300A1 (ja) 2022-03-28 2023-10-05 富士フイルム株式会社 生産物の生産方法、及び生産物
WO2023190829A1 (ja) 2022-03-31 2023-10-05 富士フイルム株式会社 生産物の製造方法、及び生産物
WO2023238949A1 (ja) 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法
JPWO2024071373A1 (enExample) 2022-09-29 2024-04-04
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093295A2 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
WO2010079510A2 (en) * 2008-12-31 2010-07-15 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
CN101646775B (zh) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
KR101618767B1 (ko) * 2008-09-02 2016-05-09 한국생명공학연구원 외래단백질을 고효율로 생산하는 리더서열
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (ko) * 2011-06-13 2014-07-21 주식회사 종근당 Ｃｓｐ－ｂ ５＇ｓａｒ 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093295A2 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
WO2010079510A2 (en) * 2008-12-31 2010-07-15 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies

Also Published As

Publication number Publication date
CN105392889A (zh) 2016-03-09
US11306323B2 (en) 2022-04-19
SG11201508447TA (en) 2015-11-27
CN114395584B (zh) 2025-01-28
US20220213500A1 (en) 2022-07-07
CN114395584A (zh) 2022-04-26
RU2015151626A3 (enExample) 2018-03-20
RU2731717C2 (ru) 2020-09-08
JP6545153B2 (ja) 2019-07-17
EP2992104A1 (en) 2016-03-09
ES2732907T3 (es) 2019-11-26
CA2910877C (en) 2021-08-03
WO2014177826A1 (en) 2014-11-06
KR20160003705A (ko) 2016-01-11
US20180127777A1 (en) 2018-05-10
BR112015027373A2 (pt) 2017-08-29
EP2992104B1 (en) 2019-04-17
RU2015151626A (ru) 2017-06-08
US9873891B2 (en) 2018-01-23
JP2016517691A (ja) 2016-06-20
DK2992104T3 (da) 2019-07-15
US20160076051A1 (en) 2016-03-17
CA2910877A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
KR102180660B1 (ko) 발현 방법
JP6748061B2 (ja) 二重シストロン細菌発現システム
KR102647165B1 (ko) 생물 제제 생산을 위한 범용 자체 조절 포유동물 세포주 플랫폼
CA3141039A1 (en) Mammalian cell lines with sirt-1 gene knockout
JP2007500016A (ja) 培養においてタンパク質生成を増大させるための方法
EP2990485B1 (en) Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody
RU2555533C9 (ru) Рекомбинантная плазмидная днк, кодирующая химерное антитело против фактора некроза опухоли-альфа человека, линия эукариотических клеток-продуцент химерного антитела и способ получения химерного антитела
JP7446342B2 (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
CN117402885A (zh) 编码泽贝妥单抗的核酸分子及其应用
JP2025510718A (ja) 哺乳動物細胞における選択マーカーとしての細菌グルタミン合成酵素
EP2922962B1 (en) Optimized expression cassette for expressing a polypeptide with high yield
JP2023550459A (ja) 抗体構築物の発現技術
CN120322561A (zh) 新型转座酶系统
WO2023238949A1 (ja) 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法
EP4650440A1 (en) Method for producing cell, method for producing multispecific antibody, vector set, mammalian cell, cho cell, and method for producing cell pool
RU2679055C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pOptiVEC-MBP84-106-Fc, КОДИРУЮЩАЯ КОНСТАНТНЫЙ ФРАГМЕНТ ИММУНОГЛОБУЛИНА ЧЕЛОВЕКА, СЛИТНОГО С ФРАГМЕНТОМ ОСНОВНОГО БЕЛКА МИЕЛИНА, ЛИНИИ ЭУКАРИОТИЧЕСКИХ КЛЕТОК - ПРОДУЦЕНТОВ УКАЗАННОГО БЕЛКА И СПОСОБ ПОЛУЧЕНИЯ БЕЛКА MBP84-106-Fc ДЛЯ ТЕРАПИИ РАССЕЯННОГО СКЛЕРОЗА
WO2015033086A1 (en) Dna construct
US20110201785A1 (en) Method for optimizing proteins having the folding pattern of immunoglobulin
HK40007802A (en) Production of seleno-biologics in genomically recoded organisms
HK1246822B (zh) 双顺反子细菌表达系统
HK1246822A1 (zh) 双顺反子细菌表达系统

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6